These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36479076)

  • 1. Dynamic alterations in PD-1/PD-L1 expression level and immune cell profiles based on radiation response status in mouse tumor model.
    Yoon YN; Choe MH; Kong M; Chung WK; Kim JS; Lim YJ
    Front Oncol; 2022; 12():989190. PubMed ID: 36479076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
    Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
    J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
    Kikuchi M; Clump DA; Srivastava RM; Sun L; Zeng D; Diaz-Perez JA; Anderson CJ; Edwards WB; Ferris RL
    Oncoimmunology; 2017; 6(7):e1329071. PubMed ID: 28811971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer.
    Zhao X; Li J; Zheng L; Yang Q; Chen X; Chen X; Yu Y; Li F; Cui J; Sun J
    Front Mol Biosci; 2022; 9():786864. PubMed ID: 35141280
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of radiotherapy-induced alteration of CD8
    Mori Y; Sato H; Kumazawa T; Permata TBM; Yoshimoto Y; Murata K; Noda SE; Kaminuma T; Ando K; Oike T; Okonogi N; Okada K; Kakoti S; Suzuki K; Ikota H; Yokoo H; Nakano T; Ohno T; Shibata A
    Oncol Lett; 2021 Jun; 21(6):446. PubMed ID: 33868484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
    Derer A; Spiljar M; Bäumler M; Hecht M; Fietkau R; Frey B; Gaipl US
    Front Immunol; 2016; 7():610. PubMed ID: 28066420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.
    Wang NH; Lei Z; Yang HN; Tang Z; Yang MQ; Wang Y; Sui JD; Wu YZ
    Ann Transl Med; 2022 Dec; 10(24):1406. PubMed ID: 36660640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model.
    Ghaffari-Nazari H; Alimohammadi M; Alimohammadi R; Rostami E; Bakhshandeh M; Webster TJ; Mahmoodi Chalbatani G; Tavakkol-Afshari J; Amir Jalali S
    Int Immunopharmacol; 2022 Jul; 108():108737. PubMed ID: 35417831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
    Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy.
    Marcq G; Evaristo G; Kool R; Shinde-Jadhav S; Skowronski R; Mansure JJ; Souhami L; Cury F; Brimo F; Kassouf W
    Eur Urol Open Sci; 2022 Sep; 43():14-21. PubMed ID: 36353066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
    Ostrand-Rosenberg S; Horn LA; Ciavattone NG
    Front Oncol; 2019; 9():215. PubMed ID: 31001479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
    Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
    Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8
    Zhu Y; Wang XY; Zhang Y; Xu D; Dong J; Zhang Z; Yi CH; Jia HL; Yang X
    Cancer Manag Res; 2018; 10():4113-4123. PubMed ID: 30323667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
    Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
    J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
    Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
    J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.